Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

The multi-receptor tyrosine kinase inhibitor XL092 has been developed to inhibit the activity of oncogenic targets, including MET, VEGFR2, and the TAM family of kinases TYRO3, AXL and MER. Presented here is a preclinical evaluation of XL092. XL092 causes a significant decrease in tumor MET and AXL p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Jeff, Chong, Colin, Serrill, Jeffrey, Goon, Levina, Balayan, Joan, Johnson, Eric N., Lorenzana, Grachelle, Wu, Sharon, Leong, Kevin G., Yun, Theodore J., Wang, Yong, Jiang, Faming, Bannen, Lynne, Lamb, Peter, Xu, Wei, Yu, Peiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890135/
https://www.ncbi.nlm.nih.gov/pubmed/36399631
http://dx.doi.org/10.1158/1535-7163.MCT-22-0262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890135/
https://www.ncbi.nlm.nih.gov/pubmed/36399631
http://dx.doi.org/10.1158/1535-7163.MCT-22-0262

Ejemplares similares